01 November 2004
Low-dose balsalazide plus a high-potency probiotic preparation is more effective than balsalazide alone or mesalazine in the treatment of acute mild-to-moderate ulcerative colitis
Antonio Tursi, Giovanni Brandimarte, Gian Marco Giorgetti, Giacomo Forti, Maria Ester Modeo, Andrea GigliobiancoMed Sci Monit 2004; 10(11): PI126-131 :: ID: 11819
Abstract
Background: Balsalazide is well tolerated and effective in treating acute ulcerative colitis. VSL#3 is a probiotic cocktail proven to be effective in preventing fl are-ups of chronic pouchitis. We compared the efficacy and safety of low-dose balsalazide (2.25 g/day) plus 3 g/day VLS#3 (group A) with mediumdose balsalazide alone (group B) and with mesalazine (group C) in the treatment of mild-to-moderate active ulcerative colitis.
Material/Methods: Ninety patients (30 per group) were randomly enrolled, with a treatment duration of 8 weeks. Efficacy was assessed by symptoms assessment, endoscopic appearance, and histological evaluation.
Results: Balsalazide/VSL#3 was significantly superior to balsalazide alone and to mesalazine in obtaining remission: 24 patients of group A were in remission [per-protocol: 85.71% (C.I.95%: 62–96), on intention-to-treat: 80% (C.I.95%: 59–91)], while 21 group B [per-protocol: 80.77% (C.I. 95%: 51–82), on intention-to-treat: 77% (C.I.95%: 43–81)] and 16 group C patients [per-protocol: 72.73% (C.I. 95%:30–75), on intention-to-treat: 53.33% (C.I.95%: 42–62)] were in remission (p<0.02). Balsalazide with or without VSL#3 was better tolerated than mesalazine: two group C patients were withdrawn from the study because of severe side-effects; 1 group A (3.33%), 3 group B (10%) and 4 group C (13.33%) patients experienced slight side-effects. The balsalazide/VSL#3 combination was faster in obtaining remission than balsalazide alone or mesalazine (4, 7.5, and 13 days in groups A, B and C, respectively) and also better in improving all parameters evaluated.
Conclusions: Balsalazide/VSL#3 may be a very good choice in the treatment of active mild-to-moderate active ulcerative colitis instead of balsalazide alone or mesalazine.
Keywords: Aminosalicylic Acids - administration & dosage, Aminosalicylic Acids - therapeutic use, Colitis, Ulcerative - drug therapy, Drug Therapy, Combination, Mesalamine - therapeutic use, Phenylhydrazines, Probiotics - therapeutic use, Aminosalicylic Acids - therapeutic use, Colitis, Ulcerative - drug therapy, Drug Therapy, Combination, Mesalamine - therapeutic use, Phenylhydrazines, Probiotics - therapeutic use
Editorial
01 March 2023 : Editorial
Editorial: Global Surveillance of Highly Pathogenic Avian Influenza Viruses in Poultry, Wild Birds, and Mammals to Prevent a Human Influenza PandemicDOI: 10.12659/MSM.939968
Med Sci Monit 2023; 29:e939968
SARS-CoV-2/COVID-19
09 February 2023 : Clinical Research
Evaluation of Health-Related Quality of Life and Mental Health in 729 Medical Students in Indonesia During ...Med Sci Monit 2023; 29:e938892
19 January 2023 : Clinical Research
Determining the Impact of the COVID-19 Pandemic on Dental Care in the Serbian Adult Population: An Online Q...Med Sci Monit 2023; 29:e939238
27 December 2022 : Clinical Research
Effect of Physiotherapy to Correct Rounded Shoulder Posture in 30 Patients During the COVID-19 Pandemic in ...Med Sci Monit 2022; 28:e938926
10 December 2022 : Clinical Research
Retrospective Study to Identify Risk Factors for Severe Disease and Mortality Using the Modified Early Warn...Med Sci Monit 2022; 28:e938647
In Press
27 Mar 2023 : Database Analysis
Relationship Between Physical Activity and Adult Asthma Control Using NHANES 2011-2020 DataMed Sci Monit In Press; DOI: 10.12659/MSM.939350
27 Mar 2023 : Clinical Research
Evaluation of the One-Hour ¹³C-Propionate Breath Test in 49 Patients from a Single Center in Japan to Detec...Med Sci Monit In Press; DOI: 10.12659/MSM.940238
24 Mar 2023 : Database Analysis
Causes of Death Following Gastric Cancer Diagnosis: A Population-Based AnalysisMed Sci Monit In Press; DOI: 10.12659/MSM.939848
22 Mar 2023 : Special report
One Year On: Poland’s Public Health Initiatives and National Response to Millions of Refugees from UkraineMed Sci Monit In Press; DOI: 10.12659/MSM.940223
Most Viewed Current Articles
13 Nov 2021 : Clinical Research
Acceptance of COVID-19 Vaccination and Its Associated Factors Among Cancer Patients Attending the Oncology ...DOI :10.12659/MSM.932788
Med Sci Monit 2021; 27:e932788
30 Dec 2021 : Clinical Research
Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis o...DOI :10.12659/MSM.935379
Med Sci Monit 2021; 27:e935379
08 Mar 2022 : Review article
A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Man...DOI :10.12659/MSM.936292
Med Sci Monit 2022; 28:e936292
01 Jan 2022 : Editorial
Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...DOI :10.12659/MSM.935952
Med Sci Monit 2022; 28:e935952